-
Je něco špatně v tomto záznamu ?
Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium
H. Li, MB. Terry, AC. Antoniou, KA. Phillips, K. Kast, TM. Mooij, C. Engel, C. Noguès, D. Stoppa-Lyonnet, C. Lasset, P. Berthet, V. Mari, O. Caron, GENEPSO study, D. Barrowdale, D. Frost, C. Brewer, DG. Evans, L. Izatt, L. Side, L. Walker, M....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
CRN-87521
CIHR - Canada
C12292/A20861
Cancer Research UK - United Kingdom
C1287/A11990
Cancer Research UK - United Kingdom
UM1 CA164920
NCI NIH HHS - United States
10118
Cancer Research UK - United Kingdom
C12292/A11174
Cancer Research UK - United Kingdom
NLK
Free Medical Journals
od 1991 do Před 1 rokem
Freely Accessible Science Journals
od 1991 do Před 12 měsíci
Open Access Digital Library
od 1991-11-01
Open Access Digital Library
od 1991-11-01
- MeSH
- dospělí MeSH
- genetická predispozice k nemoci MeSH
- heterozygot MeSH
- kouření cigaret epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- nádory prsu epidemiologie genetika prevence a kontrola MeSH
- pití alkoholu epidemiologie MeSH
- prospektivní studie MeSH
- protein BRCA1 genetika MeSH
- protein BRCA2 genetika MeSH
- reprodukční anamnéza MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- životní styl * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND: Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined these effects in BRCA1 and BRCA2 mutation carriers. Given the high breast cancer risk for mutation carriers and the importance of BRCA1 and BRCA2 in DNA repair, better evidence on the associations of these lifestyle factors with breast cancer risk is essential. METHODS: Using a large international pooled cohort of BRCA1 and BRCA2 mutation carriers, we conducted retrospective (5,707 BRCA1 mutation carriers and 3,525 BRCA2 mutation carriers) and prospective (2,276 BRCA1 mutation carriers and 1,610 BRCA2 mutation carriers) analyses of alcohol and tobacco consumption using Cox proportional hazards models. RESULTS: For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related variables was associated with breast cancer risk, except smoking for more than 5 years before a first full-term pregnancy (FFTP) when compared with parous women who never smoked. For BRCA1 mutation carriers, the HR from retrospective analysis (HRR) was 1.19 [95% confidence interval (CI), 1.02-1.39] and the HR from prospective analysis (HRP) was 1.36 (95% CI, 0.99-1.87). For BRCA2 mutation carriers, smoking for more than 5 years before an FFTP showed an association of a similar magnitude, but the confidence limits were wider (HRR = 1.25; 95% CI, 1.01-1.55 and HRP = 1.30; 95% CI, 0.83-2.01). For both carrier groups, alcohol consumption was not associated with breast cancer risk. CONCLUSIONS: The finding that smoking during the prereproductive years increases breast cancer risk for mutation carriers warrants further investigation. IMPACT: This is the largest prospective study of BRCA mutation carriers to assess these important risk factors.
All Wales Medical Genetics Services University Hospital of Wales Cardiff United Kingdom
Center for Molecular Medicine Cologne University of Cologne Cologne Germany
CLCC Antoine Lacassagne Département d'Hématologie Oncologie médicale Nice France
Clinical Genetics Guy's and St Thomas' NHS Foundation Trust London United Kingdom
Département de biopathologie Oncogénétique clinique Centre François Baclesse Caen France
Département de Médecine Gustave Roussy Hôpital Universitaire Villejuif France
Department of Clinical Genetics Fox Chase Cancer Center Philadelphia Pennsylvania
Department of Clinical Genetics Maastricht University Medical Center Maastricht the Netherlands
Department of Clinical Genetics Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
Department of Clinical Genetics Royal Devon and Exeter Hospital Exeter United Kingdom
Department of Clinical Genetics VU University Medical Center Amsterdam the Netherlands
Department of Dermatology University of Utah School of Medicine Salt Lake City Utah
Department of Epidemiology Columbia University New York New York
Department of Epidemiology Netherlands Cancer Institute Amsterdam the Netherlands
Department of Genetics and Pathology Pomeranian Medical University Unii Lubelskiej 1 Szczecin Poland
Department of Human Genetics Radboud University Medical Center Nijmegen the Netherlands
Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia
Department of Medical Oncology Prince of Wales Hospital Randwick New South Wales Australia
Department of Medical Oncology St Vincent's Hospital Fitzroy Victoria Australia
Department of Molecular Genetics National Institute of Oncology Budapest Hungary
Department of Molecular Genetics University of Toronto Toronto Ontario Canada
Department of OB GYN and Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Oncology Lund University Hospital Lund Sweden
Division of Cancer Epidemiology and Intelligence Cancer Council Victoria Melbourne Australia
Division of Cancer Medicine Peter MacCallum Cancer Centre Melbourne Victoria Australia
German Cancer Consortium Heidelberg Germany
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center New York New York
Human Genetics Group Spanish National Cancer Centre Madrid Spain
Huntsman Cancer Institute University of Utah School of Medicine Salt Lake City Utah
Inserm U830 Université Paris Descartes Paris France
Institut Curie Service de Génétique Médicale Paris France
Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Germany
Lunenfeld Tanenbaum Research Institute Sinai Health System Toronto Ontario Canada
Medical Genetics Unit St George's University of London London United Kingdom
Mines Paris Tech Fontainebleau France
Molecular Oncology Laboratory Hospital Clinico San Carlos IdISSC CIBERONC Madrid Spain
National Center for Tumor Diseases Partner Site Dresden Germany
Oxford Regional Genetics Service Churchill Hospital Oxford United Kingdom
PSL Research University Paris France
South East of Scotland Regional Genetics Service Western General Hospital Edinburgh United Kingdom
The Department of Oncology and Pathology Karolinska Institute Stockholm Sweden
The Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Australia
Wessex Clinical Genetics Service The Princess Anne Hospital Southampton United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012880
- 003
- CZ-PrNML
- 005
- 20210507101836.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1158/1055-9965.EPI-19-0546 $2 doi
- 035 __
- $a (PubMed)31792088
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Li, Hongyan $u Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah
- 245 10
- $a Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium / $c H. Li, MB. Terry, AC. Antoniou, KA. Phillips, K. Kast, TM. Mooij, C. Engel, C. Noguès, D. Stoppa-Lyonnet, C. Lasset, P. Berthet, V. Mari, O. Caron, GENEPSO study, D. Barrowdale, D. Frost, C. Brewer, DG. Evans, L. Izatt, L. Side, L. Walker, M. Tischkowitz, MT. Rogers, ME. Porteous, K. Snape, EMBRACE study, HEJ. Meijers-Heijboer, JJP. Gille, MJ. Blok, N. Hoogerbrugge, HEBON Investigators, MB. Daly, IL. Andrulis, SS. Buys, EM. John, SA. McLachlan, M. Friedlander, kConFab Investigators, YY. Tan, A. Osorio, T. Caldes, A. Jakubowska, J. Simard, CF. Singer, E. Olah, M. Navratilova, L. Foretova, AM. Gerdes, MJ. Roos-Blom, B. Arver, H. Olsson, RK. Schmutzler, JL. Hopper, RL. Milne, DF. Easton, FE. Van Leeuwen, MA. Rookus, N. Andrieu, DE. Goldgar
- 520 9_
- $a BACKGROUND: Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on the risk of breast cancer, but very few studies have examined these effects in BRCA1 and BRCA2 mutation carriers. Given the high breast cancer risk for mutation carriers and the importance of BRCA1 and BRCA2 in DNA repair, better evidence on the associations of these lifestyle factors with breast cancer risk is essential. METHODS: Using a large international pooled cohort of BRCA1 and BRCA2 mutation carriers, we conducted retrospective (5,707 BRCA1 mutation carriers and 3,525 BRCA2 mutation carriers) and prospective (2,276 BRCA1 mutation carriers and 1,610 BRCA2 mutation carriers) analyses of alcohol and tobacco consumption using Cox proportional hazards models. RESULTS: For both BRCA1 and BRCA2 mutation carriers, none of the smoking-related variables was associated with breast cancer risk, except smoking for more than 5 years before a first full-term pregnancy (FFTP) when compared with parous women who never smoked. For BRCA1 mutation carriers, the HR from retrospective analysis (HRR) was 1.19 [95% confidence interval (CI), 1.02-1.39] and the HR from prospective analysis (HRP) was 1.36 (95% CI, 0.99-1.87). For BRCA2 mutation carriers, smoking for more than 5 years before an FFTP showed an association of a similar magnitude, but the confidence limits were wider (HRR = 1.25; 95% CI, 1.01-1.55 and HRP = 1.30; 95% CI, 0.83-2.01). For both carrier groups, alcohol consumption was not associated with breast cancer risk. CONCLUSIONS: The finding that smoking during the prereproductive years increases breast cancer risk for mutation carriers warrants further investigation. IMPACT: This is the largest prospective study of BRCA mutation carriers to assess these important risk factors.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a pití alkoholu $x epidemiologie $7 D000428
- 650 _2
- $a protein BRCA1 $x genetika $7 D019313
- 650 _2
- $a protein BRCA2 $x genetika $7 D024682
- 650 _2
- $a nádory prsu $x epidemiologie $x genetika $x prevence a kontrola $7 D001943
- 650 _2
- $a kouření cigaret $x epidemiologie $7 D000073865
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a heterozygot $7 D006579
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a životní styl $7 D008019
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a reprodukční anamnéza $7 D017584
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Terry, Mary Beth $u Department of Epidemiology, Columbia University, New York, New York $u Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
- 700 1_
- $a Antoniou, Antonis C $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom
- 700 1_
- $a Phillips, Kelly-Anne $u Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Victoria, Australia $u The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia $u Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- 700 1_
- $a Kast, Karin $u Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany $u National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany $u German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
- 700 1_
- $a Mooij, Thea M $u Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- 700 1_
- $a Engel, Christoph $u Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany
- 700 1_
- $a Noguès, Catherine $u Institut Paoli-Calmettes, Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique and Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France
- 700 1_
- $a Stoppa-Lyonnet, Dominique $u Institut Curie, Service de Génétique Médicale, Paris, France $u Inserm, U830, Université Paris Descartes, Paris, France
- 700 1_
- $a Lasset, Christine $u Unité de prévention et Epidémiologie Génétique, Centre Léon Bérard - Lyon/UMR CNRS 5558, Université de Lyon - Lyon, France
- 700 1_
- $a Berthet, Pascaline $u Département de biopathologie, Oncogénétique clinique, Centre François Baclesse - Caen, France
- 700 1_
- $a Mari, Veronique $u CLCC Antoine Lacassagne, Département d'Hématologie - Oncologie médicale, Nice, France
- 700 1_
- $a Caron, Olivier $u Département de Médecine, Gustave Roussy Hôpital Universitaire - Villejuif, France
- 700 1_
- $a Barrowdale, Daniel $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom
- 700 1_
- $a Frost, Debra $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom
- 700 1_
- $a Brewer, Carole $u Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, United Kingdom
- 700 1_
- $a Evans, D Gareth $u Genomic Medicine, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, Manchester University, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
- 700 1_
- $a Izatt, Louise $u Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- 700 1_
- $a Side, Lucy $u Wessex Clinical Genetics Service, The Princess Anne Hospital, Southampton, United Kingdom
- 700 1_
- $a Walker, Lisa $u Oxford Regional Genetics Service, Churchill Hospital, Oxford, United Kingdom
- 700 1_
- $a Tischkowitz, Marc $u University of Cambridge Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, and Cancer Research UK Cambridge Center, Cambridge Biomedical Campus, Cambridge, United Kingdom
- 700 1_
- $a Rogers, Mark T $u All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, United Kingdom
- 700 1_
- $a Porteous, Mary E $u South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom
- 700 1_
- $a Snape, Katie $u Medical Genetics Unit, St. George's, University of London, London, United Kingdom
- 700 1_
- $a Meijers-Heijboer, Hanne E J $u Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands
- 700 1_
- $a Gille, Johan J P $u Department of Clinical Genetics, VU University Medical Center, Amsterdam, the Netherlands
- 700 1_
- $a Blok, Marinus J $u Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands
- 700 1_
- $a Hoogerbrugge, Nicoline $u Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
- 700 1_
- $a Daly, Mary B $u Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania
- 700 1_
- $a Andrulis, Irene L $u Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada $u Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada
- 700 1_
- $a Buys, Saundra S $u Department of Medicine, University of Utah Health Sciences Center, Huntsman Cancer Institute, Salt Lake City, Utah
- 700 1_
- $a John, Esther M $u Stanford University School of Medicine, Department of Medicine, Division of Oncology, and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California
- 700 1_
- $a McLachlan, Sue-Anne $u Department of Medicine, St. Vincent's Hospital, The University of Melbourne, Parkville, Victoria, Australia $u Department of Medical Oncology, St. Vincent's Hospital, Fitzroy, Victoria, Australia
- 700 1_
- $a Friedlander, Michael $u Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia $u Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- 700 1_
- $a Tan, Yen Y $u Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Osorio, Ana $u Human Genetics Group, Spanish National Cancer Centre (CNIO) and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
- 700 1_
- $a Caldes, Trinidad $u Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, CIBERONC (ISCIII), Madrid, Spain
- 700 1_
- $a Jakubowska, Anna $u Department of Genetics and Pathology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, Poland $u Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland
- 700 1_
- $a Simard, Jacques $u Genomics Center, Centre Hospitalier Universitaire de Québec - Université Laval Research Center, Quebec City, Quebec, Canada
- 700 1_
- $a Singer, Christian F $u Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Olah, Edith $u Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary
- 700 1_
- $a Navratilova, Marie $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, Czech Republic
- 700 1_
- $a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, Czech Republic
- 700 1_
- $a Gerdes, Anne-Marie $u The Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden
- 700 1_
- $a Roos-Blom, Marie-José $u Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- 700 1_
- $a Arver, Brita $u Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark $u Department of Oncology, Lund University Hospital, Lund, Sweden
- 700 1_
- $a Olsson, Håkan $u Department of Oncology, Lund University Hospital, Lund, Sweden
- 700 1_
- $a Schmutzler, Rita K $u Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany $u Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
- 700 1_
- $a Hopper, John L $u Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Victoria, Australia
- 700 1_
- $a Milne, Roger L $u Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Victoria, Australia $u Division of Cancer Epidemiology and Intelligence, Cancer Council Victoria, Melbourne, Australia $u Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
- 700 1_
- $a Easton, Douglas F $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom $u Centre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Research Laboratory, Worts Causeway, University of Cambridge, Cambridge, United Kingdom
- 700 1_
- $a Van Leeuwen, Flora E $u Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- 700 1_
- $a Rookus, Matti A $u Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- 700 1_
- $a Andrieu, Nadine $u INSERM, U900, Paris, France. david.goldgar@hsc.utah.edu nadine.andrieu@curie.fr $u Institut Curie, Paris, France $u Mines Paris Tech, Fontainebleau, France $u PSL Research University, Paris, France
- 700 1_
- $a Goldgar, David E $u Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah. david.goldgar@hsc.utah.edu nadine.andrieu@curie.fr $u Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah
- 710 2_
- $a GENEPSO study
- 710 2_
- $a EMBRACE study
- 710 2_
- $a HEBON Investigators
- 710 2_
- $a kConFab Investigators
- 773 0_
- $w MED00006442 $t Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology $x 1538-7755 $g Roč. 29, č. 2 (2020), s. 368-378
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31792088 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101835 $b ABA008
- 999 __
- $a ok $b bmc $g 1651120 $s 1133259
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 29 $c 2 $d 368-378 $e 20191202 $i 1538-7755 $m Cancer epidemiology, biomarkers & prevention $n Cancer Epidemiol Biomarkers Prev $x MED00006442
- GRA __
- $a CRN-87521 $p CIHR $2 Canada
- GRA __
- $a C12292/A20861 $p Cancer Research UK $2 United Kingdom
- GRA __
- $a C1287/A11990 $p Cancer Research UK $2 United Kingdom
- GRA __
- $a UM1 CA164920 $p NCI NIH HHS $2 United States
- GRA __
- $a 10118 $p Cancer Research UK $2 United Kingdom
- GRA __
- $a C12292/A11174 $p Cancer Research UK $2 United Kingdom
- LZP __
- $a Pubmed-20210420
